NCT07086326View on ClinicalTrials.gov

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
NSCLCNeoadjuvant TherapyImmunotherapyAK112Bispecific Antibody
Interventions
DRUG

Ivonescimab+Chemo

Ivonescimab (AK112) + platinum-based doublet chemotherapy

DRUG

Penpulimab+Chemo

Penpulimab (AK105) + platinum-based doublet chemotherapy

Trial Locations (5)

100000

Peking University People's Hospital, Beijing

Unknown

Hunan Cancer Hospital, Changsha

Shanghai Chest Hospital, Shanghai

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Yang Fan, MD

OTHER